NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Theresa Heah
Kriya Therapeutics is launching a new division, Kriya Ophthalmology, focused on developing gene therapies for rare and prevalent ocular diseases.
BioSkrybe's new facility
BioSkrybe logo

The Durham-based genetics startup BioSkryb has relocated into bigger digs.

UNC's CRISPR Genetic & Epigenetic Screening Center opens Oct. 1, with powerful new technology that received funding support from NCBiotech.
Opus logo
The Retinal Degeneration Fund is spinning out its own Raleigh-based biotech startup, Opus Genetics, aiming at curing blindness after landing $19 million in seed financing.
GreenLight field trial spraying RNA pesticide
GreenLight Biosciences, with a growing R&D site in RTP, is the latest local company to go public using a SPAC, to accelerate its development of RNA products for human health and agriculture.
Shutterstock image of gene snip
Durham-based gene editing company Precision Biosciences has inked a deal with gene editing company iECURE to advance one of Precision’s drug candidates into Phase 1 clinical studies
Bluebird bio
Bluebird bio, a Massachusetts-based gene and cell therapy company with operations in North Carolina, will sell its Durham biomanufacturing plant to National Resilience for $110 million as part of a strategic alliance between the two companies.
Kriya leadership
Kriya Therapeutics is poised to revolutionize gene therapies for highly serious diseases like diabetes and severe obesity after landing a whopping $100 million in capital.
Inceptor Bio logo
A Raleigh biotechnology startup is putting an initial $26 million investment into the establishment of a teamwork approach to enhance efficiencies for cell- and gene-based cancer therapy developers.
Bluebird bio exterior
Bluebird bio, a gene therapy company with manufacturing facilities in Durham, is resuming clinical trials of potential therapies for two inherited blood disorders after clearance from the FDA.
Galleri test kit
GRAIL's new blood test that can detect more than 50 types of cancer in a single blood draw is now available in the United States with a prescription.
CARsgen logo
Shanghai-based cancer immunotherapy innovator CARsgen has announced plans to invest $157 million to establish a Durham site that will employ 200 people over the next few years.
Kelli, Ash
A trio of Triangle scientists is launching Isolere Bio, bootstrapped with a $250K NCBiotech loan that led to $7 million in seed funding attracted by the technology they believe can allow gene therapy companies to vastly increase the number of doses they can produce.
Matt Hirsch with patients in California
UNC-affiliated startup RainBio is parlaying support from NCBiotech to develop a novel gene therapy for corneal blindness, giving patients a chance not only for longer lives, but better ones.
Invitae saliva test kit
Invitae logo

San Francisco-based medical genetics testing company Invitae is investing $114.6 million to bring its wide-ranging medical testing capability to North Carolina, adding 374 life sc